Novartis Ag (NVS) Non-Current Debt (2010 - 2017)

Novartis Ag has disclosed Non-Current Debt across 8 years of filings, most recently posting -$23.2 billion for Q3 2017.

• In Q3 2017, Non-Current Debt fell 26.86% year-over-year to -$23.2 billion; the TTM figure through Sep 2017 stood at -$23.2 billion (down 26.86% YoY), while the FY2015 annual figure was -$16.3 billion, down 18.32% from the prior year.
• Non-Current Debt came in at -$23.2 billion for Q3 2017 at Novartis Ag, down from -$23.0 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of -$11.6 billion in Q1 2013 to a low of -$23.2 billion in Q3 2017.
• Average Non-Current Debt over 5 years is -$16.8 billion, with a median of -$16.3 billion recorded in 2016.
• Year-over-year, Non-Current Debt advanced 16.45% in 2013 and slumped 41.31% in 2017.
• Over 5 years, Non-Current Debt stood at -$11.6 billion in 2013, then retreated by 18.85% to -$13.8 billion in 2014, then fell by 18.32% to -$16.3 billion in 2015, then dropped by 11.83% to -$18.3 billion in 2016, then declined by 26.86% to -$23.2 billion in 2017.
• Per Business Quant data, the three most recent Non-Current Debt figures were -$23.2 billion in Q3 2017, -$23.0 billion in Q2 2017, and -$22.9 billion in Q1 2017.